Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025

Assessing the impact of a second IVIG dose on patients with Guillain-Barré Syndrome: A synthesis without meta-analysis (SWiM).

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMohammad M. AlnaeemAl-Zaytoonah University of JordanAAAhmad R. Al‐QudimatHamad Medical CorporationDTDoaa TalafhaAl-Zaytoonah University of Jordan

Discussion

Loading...

Member takes

Implication

Systematic review evaluates clinical outcomes of a second IVIG dose in Guillain-Barré patients, suggesting improved outcomes and reduced ventilator dependency.

Key Points

  • A second IVIG dose may significantly improve motor symptoms in Guillain-Barré syndrome patients, indicating potential treatment benefits.
  • Seventy percent of studies reported clinical motor improvement after the second IVIG dose, highlighting its relevance in patient care.
  • Quality assessment was performed using the Joanna Briggs Institute tools, ensuring reliable evaluation of included studies.
  • The review covered 10 studies with 94 patients, emphasizing the need for further randomized trials to strengthen the findings.

Cite This Study

Alnaeem et al. (2025) studied this question.

synapsesocial.com/papers/68e02f2cf0e39f13e7fa1f6ahttps://doi.org/10.5339/qmj.2025.88
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis2023 · 40 citations
  2. 2Treatment of Guillain‐Barre syndrome with high‐dose gammaglobulin1988 · 233 citations
  3. 3The Effectiveness of Plasmapheresis Compared to Intravenous Immunoglobulin in Guillain-Barre Syndrome Patients2024 · 1 citations
  4. 4Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain–Barré syndrome2025 · 2 citations
  5. 5Intravenous Efgartigimod or Intravenous Immunoglobulin in Guillain‐Barre Syndrome: An Observational Multicenter Study2025 · 3 citations